This law firm has not supplied any contact details or supplementary information for this country or region. For more information about profiling options please contact Prin Shasiharan.
Linked Reviews
Dispute Resolution
Boutique firm Gruenstein Law has quickly established a presence in New York’s disputes market following its launch in 2026. The firm advises companies, boards, senior executives and individuals on government investigations, white-collar criminal defense, regulatory enforcement and complex civil litigation.
Founder Benjamin Gruenstein is the firm’s principal figure. His practice spans white-collar defense and investigations, appellate litigation, False Claims Act matters and trade secrets disputes. He demonstrates notable appellate capability through Fernandez v. United States, in which he argued before the US Supreme Court in a closely watched case addressing the permissible scope of compassionate-release considerations under the First Step Act.
Gruenstein also represents Novartis Pharmaceuticals in US ex rel. Camburn v. Novartis Pharmaceuticals Corp., an ongoing False Claims Act whistleblower action concerning alleged physician-speaker-program kickbacks. Following a partial reversal by the Second Circuit, the matter advanced after a renewed motion to dismiss was denied in March 2026.
The firm’s broader commercial disputes credentials are illustrated by its representation of Cintra Global and Cintra Holding US in litigation against a former senior executive. The ongoing Texas trade secrets dispute concerns allegations involving the removal of confidential business materials relevant to major US infrastructure projects.
Although compact, Gruenstein Law offers experience across trial, appellate and investigative proceedings, with particular strength in consequential white-collar, whistleblower and trade secrets matters.
Updated October 2026
Founder Benjamin Gruenstein is the firm’s principal figure. His practice spans white-collar defense and investigations, appellate litigation, False Claims Act matters and trade secrets disputes. He demonstrates notable appellate capability through Fernandez v. United States, in which he argued before the US Supreme Court in a closely watched case addressing the permissible scope of compassionate-release considerations under the First Step Act.
Gruenstein also represents Novartis Pharmaceuticals in US ex rel. Camburn v. Novartis Pharmaceuticals Corp., an ongoing False Claims Act whistleblower action concerning alleged physician-speaker-program kickbacks. Following a partial reversal by the Second Circuit, the matter advanced after a renewed motion to dismiss was denied in March 2026.
The firm’s broader commercial disputes credentials are illustrated by its representation of Cintra Global and Cintra Holding US in litigation against a former senior executive. The ongoing Texas trade secrets dispute concerns allegations involving the removal of confidential business materials relevant to major US infrastructure projects.
Although compact, Gruenstein Law offers experience across trial, appellate and investigative proceedings, with particular strength in consequential white-collar, whistleblower and trade secrets matters.
Updated October 2026
